A universal recipient for protein production in eggs

描述（由申请人提供）：迄今为止，通过将胚盘细胞或胚胎干细胞注射到X期胚胎（受体）中来制备嵌合鸡，但嵌合的频率和水平是可变的和不可预测的（Petitte等人，1990; Petitte等人，1993年）。我们正在开发一种贡献最小的通用受体，以便供体来源的细胞对所产生的嵌合体的贡献始终是高的和可预测的。 一旦嵌合体开始产蛋，并且在它们将编码生物药物蛋白的基因传递给下一代之前，这些高级嵌合体就可以用于在鸡蛋中产生生物药物蛋白。此外，如果转基因干扰它们的繁殖能力，这些高级嵌合体将允许生物药物蛋白质的生产。 这项研究的终点是一个强大的系统，以高度可预测的方式产生高等级的嵌合体。使用该系统，可以在可扩展的系统中以最低的成本快速生产生物制药蛋白质。

DESCRIPTION (provided by applicant): To date, chimeric chickens are made by injecting blastodermal cells or embryonic stem cells into the stage X embryo (recipient), but the frequency and level of chimerism is variable and unpredictable (Petitte et al., 1990; Petitte et al., 1993). We are developing a universal recipient that contributes minimally, so that the contribution of donor derived cells to the resulting chimera is constantly high and predictable. These high-grade chimeras can be used to produce biopharmaceutical proteins in chicken eggs as soon as the chimeras commence laying and before they transmit the gene encoding the biopharmaceutical protein to the next generation. In addition, these high-grade chimeras will allow the production of biopharmaceutical proteins if the transgene interferes with their ability to reproduce. The end point of this research is a robust system to produce high-grade chimeras in highly predictable way. Using this system biopharmaceutical proteins can be produced quickly, in a scalable system and at minimal cost.